- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03229564
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children
February 7, 2023 updated by: CUTISS AG
A Phase IIb, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Partial Deep Dermal and Full Thickness Burns in Children in Comparison to Autologous Split-thickness Skin Grafts (STSG)
This phase IIb trial aims to evaluate the efficacy and safety of EHSG-KF (synonym denovoSkin) in comparison to meshed STSG in children with partial deep dermal and full thickness burns.
Study Overview
Detailed Description
This multicentre phase IIb clinical trial will target patients from 1-17 years with severe burns to elucidate the benefit of a tissue-engineered autologous skin substitute for the patient group with the highest mortality rates.
Particular emphasis, apart from safety, will be placed on efficacy, including the ratio of covered surface area to harvested surface area and scar quality, in comparison to meshed STSG.
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Napoli, Italy
- Recruiting
- Unità di Chirurgia Plastica e Ustioni Ospedale Santobono
-
Padova, Italy
- Recruiting
- U.O.C. Grandi Ustionati Azienda Ospedale Università Padova
-
Torino, Italy, 10126
- Not yet recruiting
- Città della Salute
-
Verona, Italy
- Not yet recruiting
- U.O. Chirurgia Plastica e Centro Ustioni Azienda Ospedaliera Universitaria Integrata Verona
-
Principal Investigator:
- Jasminka Minic
-
-
-
-
-
Beverwijk, Netherlands, 1940
- Recruiting
- Rode Kruis Ziekenhuis
-
-
-
-
-
Zurich, Switzerland, 8032
- Recruiting
- University Children's Hospital Zurich
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 12 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: <12 years of age
- Deep partial thickness and/or full-thickness burns requiring surgical wound coverage
- Expected that ≥90 cm2 of wound (not counting the head and neck area for study patients in The Netherlands) will remain open at 4 weeks post burn despite proceeding with treatment in accordance with the standard of care. >20% TBSA burns can be taken as guideline, but TBSA is not an inclusion criterion.
- Signed Informed consent
Exclusion Criteria:
- Patients tested positive for HBV, HCV, syphilis or HIV
- Patients with known underlying or concomitant medical conditions that may interfere with normal wound healing (e.g. systemic skin and connective tissue diseases, any kind of congenital defect of metabolism including insulin-dependent diabetes mellitus, Cushing syndrome or disease, scurvy, chronic hypothyroidism, congenital or acquired immunosuppressive condition, chronic renal failure, or chronic hepatic dysfunction (Child-Pugh class B or C), severe malnutrition, or other concomitant illness which, in the opinion of the Investigator, has the potential to significantly delay wound healing)
- Severe drug and alcohol abuse
- Patients with a known history of malignancy
- Pre-existing coagulation disorders as defined by INR outside its normal value, PTT >ULN and fibrinogen <LLN prior to the current hospital admission and / or at the Investigator's discretion
- Patients with known allergies to amphotericin B, gentamicin, penicillin, streptomycin, or bovine collagen
- Previous enrolment of the patient into the current phase II study
- Participation of the patient in another study with conflicting endpoints within 30 days preceding and during the present study
- Patients or parents/legal guardian expected not to comply with the study protocol (including patients with severe cognitive dysfunction/impairment and severe psychiatric disorders)
- Pregnant or breast feeding females
- Suspicion of child abuse
- Wounds in the head and neck area as study target area (only applicable for study patients in The Netherlands)
- Enrolment of the Investigator, his/her family members, employees and other dependent persons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: EHSG-KF and STSG Transplantation
Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
|
Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
Other Names:
Transplantation of autologous split-thickness skin graft to the control area
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of EHSG-KF in comparison to meshed STSG based on ratio of covered surface
Time Frame: 4 weeks post grafting
|
Efficacy of EHSG-KF in comparison to meshed STSG based on ratio of covered surface area to biopsy site/donor site surface area
|
4 weeks post grafting
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of EHSG-KF in comparison to meshed STSG based on clinical signs of infection
Time Frame: 4-11 days post grafting and 21 +/-2 days post grafting
|
Evaluation of clinical signs of infection at experimental area and control area
|
4-11 days post grafting and 21 +/-2 days post grafting
|
Safety of EHSG-KF in comparison to meshed STSG based on microbiological signs of infection
Time Frame: 4-11 days post grafting and 21 +/-2 days post grafting
|
Evaluation of microbiologic signs of infection at experimental area and control area
|
4-11 days post grafting and 21 +/-2 days post grafting
|
Efficacy of EHSG-KF in comparison to meshed STSG based on evaluation of scar quality by measurement of the elasticity using Cutometer(R)
Time Frame: 1 year +/-30 days post grafting
|
Assessment of elasticity of experimental area and control area using Cutometer(R)
|
1 year +/-30 days post grafting
|
Efficacy of EHSG-KF in comparison to meshed STSG based on evaluation of scar quality by assessment of general scar quality using POSAS assessment tool
Time Frame: 1 year +/-30 days post grafting
|
Assessment of general scar quality of experimental area and control area using POSAS assessment tool
|
1 year +/-30 days post grafting
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 25, 2017
Primary Completion (ANTICIPATED)
December 1, 2023
Study Completion (ANTICIPATED)
December 1, 2025
Study Registration Dates
First Submitted
July 7, 2017
First Submitted That Met QC Criteria
July 21, 2017
First Posted (ACTUAL)
July 25, 2017
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 7, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TBRU-dS-BC-PIIb
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
RenovaCare, IncActive, not recruitingBurns | Burns Second Degree | Burns Deep Second DegreeUnited States
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
-
Sun Yat-sen UniversityCompleted
-
MediWound LtdActive, not recruitingThermal BurnsUnited States, United Kingdom, Spain, Georgia, Belgium, Poland, Germany, Hungary, India, Italy, Netherlands, Romania, Slovakia, Ukraine
-
Virginia Commonwealth UniversityNot yet recruiting
-
The Hong Kong Polytechnic UniversityCompleted
-
St. Justine's HospitalRecruiting
Clinical Trials on EHSG-KF
-
CUTISS AGUniversity of Zurich; University Hospital, Zürich; Julius Clinical; Sintesi Research... and other collaboratorsActive, not recruitingBurnsSwitzerland, Netherlands, Italy
-
CUTISS AGUniversity of Zurich; University Hospital, Zürich; Julius Clinical; Sintesi Research... and other collaboratorsActive, not recruitingSkin WoundSwitzerland, Italy, Netherlands
-
Keythera Pharmaceuticals (Australia) Pty LtdRecruitingGastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the EsophagusAustralia
-
Kessler FoundationCompleted
-
Kessler FoundationRecruitingTraumatic Brain InjuryUnited States
-
Kessler FoundationCompletedAutism Spectrum Disorder | Autism | ASDUnited States
-
Kessler FoundationRecruiting
-
Federal University of UberlandiaCompletedDentin Sensitivity | Dentin Hypersensitivity | Dentine Hypersensitivity | Hypersensitivity DentinBrazil
-
Kessler FoundationNational Multiple Sclerosis SocietyRecruitingMultiple SclerosisUnited States
-
Kessler FoundationNYU Langone HealthCompleted